We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · August 04, 2020

Improved Efficacy WIth Nivolumab Plus Ipilimumab in Patients With Advanced RCC

Journal for immunotherapy of cancer


Additional Info

Journal for immunotherapy of cancer
Survival Outcomes and Independent Response Assessment With Nivolumab Plus Ipilimumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma: 42-Month Follow-Up of a Randomized Phase 3 Clinical Trial
J Immunother Cancer 2020 Jul 01;8(2)e000891, RJ Motzer, B Escudier, DF McDermott, O Arén Frontera, B Melichar, T Powles, F Donskov, ER Plimack, P Barthélémy, HJ Hammers, S George, V Grünwald, C Porta, V Neiman, A Ravaud, TK Choueiri, BI Rini, P Salman, CK Kollmannsberger, SS Tykodi, MO Grimm, H Gurney, R Leibowitz-Amit, PF Geertsen, A Amin, Y Tomita, MB McHenry, SS Saggi, NM Tannir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading